Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.36 |
| ▸ | PRKCI | P41743 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22448318 | 1.00 | TLR8 (0.36) | TLR8TLR7PRKCIKCNH2KDM4E | |
| SCHEMBL22448349 | 0.81 | TAS1R3 (0.32) | KDM4ENPSR1TAS1R3TAS1R1ADORA3 | |
| SCHEMBL17829990 | 0.79 | TLR8 (0.53) | TLR8TLR7KCNH2CYP2D6CXCR2 | |
| SCHEMBL22448324 | 0.79 | TLR8 (0.53) | TLR8TLR7KCNH2CYP2D6CXCR2 | |
| SCHEMBL21536698 | 0.79 | TLR8 (0.41) | TLR8TLR7KCNH2CYP2D6ADORA2A | |
| SCHEMBL17829981 | 0.79 | TLR8 (0.41) | TLR8TLR7KCNH2CYP2D6ADORA2A | |
| SCHEMBL17829991 | 0.78 | KCNH2 (0.56) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL22448320 | 0.78 | KCNH2 (0.56) | TLR8TLR7KCNH2CYP2D6 | |
| SCHEMBL22448319 | 0.75 | TLR8 (0.42) | TLR8TLR7PRKCIKCNH2 | |
| SCHEMBL17829993 | 0.75 | TLR8 (0.54) | TLR8TLR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822347-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-03 | — | — | US | disclosed |
| EP-3404031-B1 | THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-09-23 | — | — | EP | disclosed |
| US-20190330227-A1 | THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-31 | — | — | US | disclosed |
| US-10316043-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2019-06-11 | — | — | US | disclosed |
| US-20170298079-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298079-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-19 | — | — | US | disclosed |
| US-9556199-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-9556199-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-20160168164-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
| US-20160168164-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168164-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMS, TYMP, UMPS | TLR8 1457/4885TLR7 766/4885PRKCI 3542/4885 |
| US-20190330227-A1 | THIENO[3,2-D]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMS, TYMP, UMPS | TLR8 1457/4885TLR7 766/4885PRKCI 3542/4885 |
| US-20170298079-A1 | THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMS, TYMP, UMPS | TLR8 1457/4885TLR7 766/4885PRKCI 3542/4885 |
| US-10316043-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | TYMS, TYMP, UMPS | TLR8 1457/4885TLR7 766/4885PRKCI 3542/4885 |
| US-10822347-B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | TYMS, TYMP, UMPS | TLR8 1457/4885TLR7 766/4885PRKCI 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.